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Figure 1: OP projections
Conclusion: As the regression line and its equation represents an acceptable estimate
of the true relationship between Cranial/Caudal and LAO/RAO, to determine OP while
remaining around the regression line we suggest starting in LAO = 8.9, Caudal = -10.6
(the mean of these two variables) and increasing the caudal angle by approximately
0.5 degrees for every increase of 1 degree of the LAO or decreasing the caudal angle
by 0.5 degree for every decrease of 1 degree in LAO until all 3 aortic sinuses are in
line which represents OP.
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Background: Transcatheter aortic valve replacement (TAVR) is increasingly being
advocated for treating surgically inoperable or high risk patients with severe
symptomatic aortic stenosis. Its use in treating failing surgical aortic bioprosthetic valve
is also increasing. We report our TAVR findings in Northern Ireland.
Methods: All patients who met the clinically and technical criteria (annulus ranging
from 19.5 to 27mm; vascular access more than 6mm in diameter) were discussed and
approved for the procedure at a joint multidisciplinary meeting. Unless a patient
required a cut-down for vascular access, all cases were performed under local
anaesthesia and without sedation. All patients were managed immediately post-
procedure in the Coronary Care Unit. All patients underwent clinical,
echocardiographic assessments and 6 minute walk test at pre-procedure, pre-discharge,
30day, 3month, 6 month, 12 month and 6 monthly thereafter.
Results: A total of 120 patients (average age: 83yrs old; Average logistic euroscore:24)
were planned for TAVR. Procedural success was 98% (1 procedural related mortality
and the valve was not delivered in 1 patient due to access difficulty), with 91.8%
performed under local anaesthesia. Percutaneous vs access cutdown (subclavian or
femoral artery) were 91.8% and 8.2% respectively. TAVI was performed for failing
native aortic valve in 94.1% and bioprosthetic valve (valve-in-valve) in 5.9% of
patients. The 30-day, 6-month and 1-year all cause mortality were 4.7%, 7% and 11.6%
respectively. Minor vascular access complication (by VARC definition) was 2.4%
(major=0%). Clinical stroke was observed in X2 patients and gut ischaemia presumed
embolic event was observed in 1 patient: all were in atrial fibrillation and were either
unable to be prescribed warfarin or had it stopped for another procedure.
Conclusion: Conclusions: In carefully pre-selected patients, TAVR performed by a
dedicated team is safe and efficacious. Performing the procedure under local
anaesthesia has merits. Pre-existence of untreated atrial fibrillation correlates with
increased risk of embolic events.
TCT-750
The STS-Score outperforms the EuroSCORE in predicting short-term outcome
following transcatheter valve implantation, but does not predict long-term
outcome
Ralf Lehmann1, Kathrin Hemann1, Johannes Weber2, Margarita Sirotina2, Horst
Sievert2, Nina Wunderlich2, Anton Moritz1, Andreas M Zeiher1, Volker Schächinger3,
Mirko Doss1, Stephan Fichtlscherer1
1University Hospital Frankfurt, Frankfurt, Germany; 2CardioVascular Center
Frankfurt, Frankfurt, Germany; 3Hospital Fulda, Fulda, Germany
Background: Transcatheter aortic valve implantation (TAVI) was developed as new
therapy for inoperable patients and surgical high-risk patients. After successful index
procedure further prognosis might be influenced mainly by comorbidities. Therefore,
patient selection seems to be crucial in order to improve short and long-term outcome.
The aim of this study was to identify predictors of adverse outcome
Methods: Until today a total of 132 transfemoral (TF) and 122 transapical TAVI
procedures were performed at the University Hospital Frankfurt. Beyond evaluation
of clinical and functional characteristics Euroscore, STS and Braden-Score were
calculated for each of these patients.
Results: Observed 30-day Mortality was 5% in the femoral and 15% in the apical
patients. In the transfemoral cohort the EuroSCORE was significantly lower compared
to the transapical cohort (16.5±12.6 vs. 22.7±15.8 ; p=0.001). Patients with a STS-
Score (range 34.9) above the median (5.4) experienced a nearly threefold elevated
30-day-mortality (HR 2.78; p=0.048), whereas the logistic EuroSCORE (HR 1.74;
p=0.237) and the Braden-Score (HR 0.79; p=0.629) were no predictors. Furthermore
age above 80 years is associated with a dramatically elevated 30-day-mortality (HR
6.35; p=0.013). The hazard ratio (HR) of TF cases was 0.38 (p=0.044) compared to
TA cases. In a multivariable analysis only age above 80 years remains as independent
predictor of adverse acute outcome (HR 5.27; p=0.027). In a subgroup of 162 patients
predictors of long-term mortality were calculated (follow-up 379±341 days). These
analysis was restricted patients discharged alive (follow-up 379±341 days). Neither
the STS-Score (HR 1.08; p=0.837) nor the EuroSCORE (HR 1.36; p=0.470) or age
(HR 0.74; p=0.435) were predictors of long-term mortality. No any other independent
risk predicting factors including analysis of echocardiographic data could be found.
Conclusion: The STS-Score outperforms the logistic EuroSCORE in predicting 30-
day-mortality following TAVI, but does not predict long-term outcome.
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Background: Transcatheter aortic valve implantation (TAVI) via transfemoral route
had been demonstrated with most favourable clinical outcomes. However, for patients
with no suitable transfemoral access, other approaches would be adopted, namely
Trans-axillary (TAx), Direct aortic (DA) utilizing CoreValve and Transapical (TA)
utilizing Edwards-SAPIEN valve. We report our experience and patient outcome in
TAVI via non-transfemoral approach utilizing CoreValve.
Methods: For patients accepted for TAVI, access route suitability would be assessed
by conventional and CT angiograms, taking into account the vessel size, tortuosity,
presence of peripheral vascular disease (PVD) and patent LIMA graft. TAVI was
performed under general anaesthesia and in usual fashion as described in literature.
Procedural success was defined as successful implantation of CoreValve without >2+
aortic regurgitation (AR). Patients were followed up clinically and with
echocardiography at 30 days and 1 year.
Results: Out of 197 patients undergone TAVI in our institution, 33 patients (22 males,
66.7%) had TAVI via non-transfemoral approach: 10 direct aortic (5.1%) and 23 trans-
axillary (11.7%). The two groups were not different in terms of age (p=0.7), left
ventricular ejection fraction (LVEF) (p=0.06) and prevalence of PVD (p=0.9). Logistic
EuroSCORE was 26.3±12.3 for DA and 12.4±8.1 for TAx approaches (p=0.13). 100%
procedural success was achieved in both groups. There was no difference in terms of
incidence of paravalvular AR post-TAVI (p=0.49). 30-day mortality was 10% in DA
group (1 patient died from post-operative ischaemic stroke at 23 days) and 4.3% in
TAx group (1 patient with severe PVD died from ischaemic bowel due to thrombosis
of superior mesenteric artery at 29 days). 1-year mortality was 20% in DA group and
13% in TAx group (p=0.34).
Conclusion: Among different non-transfemoral approaches for TAVI utilizing
CoreValve, both direct aortic and trans-axillary approaches were shown to be safe and
feasible alternatives to transfermoral approach in patients with no suitable femoral
access.
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